Quince Therapeutics, Inc. (QNCX) Stock Price & Analysis
Quince Therapeutics, Inc. (QNCX) fell 3.00% to USD 0.97 as of June 10, 2026 at 02:25 UTC, according to Nexqual real-time market data.
QNCX last closed at USD 1; the session ranged USD 0.96–1.01 on volume of 804,714 shares. Market capitalization is $18.97M, with a 52-week range of USD 0.79–45.5 (NMS). Source: Nexqual, June 10, 2026 at 02:25 UTC.
Key Statistics (as of June 10, 2026 at 02:25 UTC)
| Price | USD 0.97 |
|---|---|
| Change | ▼ 3.00% (down) |
| Previous Close | USD 1 |
| Open | USD 0.99 |
| Day Range | USD 0.96 – 1.01 |
| 52-Week Range | USD 0.79 – 45.5 |
| Volume | 804,714 shares |
| Market Cap | $18.97M |
| Exchange | NMS |
Technical Analysis (QNCX)
Nexqual's technical model rates QNCX "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.36 (neutral) |
| vs SMA50 | Below (USD 1.2) |
| MACD | -0.08 (negative) |
Analyst Ratings (QNCX)
Wall Street analysts rate QNCX "None" based on 1 analysts, per Nexqual as of June 10, 2026 at 02:25 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 0 |
| High Target | USD 0 |
| Low Target | USD 0 |
Earnings (QNCX)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -2.3 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.88 vs est -2.3 ▲ beat |
| 2025-12-31 | USD -7.6 vs est -2.25 ▼ miss |
| 2025-09-30 | USD -2.5 vs est -2.23 ▼ miss |
| 2025-06-30 | USD -3.25 vs est -2.33 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financials & Fundamentals (QNCX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -192.90% |
| Debt / Equity | 1.87 |
| Current Ratio | 2.92 |
| Total Cash | $18.16M |
| Total Debt | $293,000 |
| Free Cash Flow | $-30.58M |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financial Health Score (QNCX)
Nexqual rates Quince Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:25 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $18M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$39M |
| Efficiency | Critical — ROE -193%, ROA -45.4% |
Ownership (QNCX)
| Insider Ownership | +3.19% |
|---|---|
| Institutional Ownership | +9.98% |
| Shares Outstanding | 19.56M |
| Float | 15.71M |
| Short % of Float | +10.56% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Leadership (QNCX)
Quince Therapeutics, Inc. is led by Dirk Thye (age 55), CEO, Chief Medical Officer & Director, per Nexqual as of June 10, 2026 at 02:25 UTC.
| CEO, Chief Medical Officer & Director | Dirk Thye (age 55) |
|---|---|
| President | Charles S. Ryan (age 61) |
| Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer | Brendan Hannah (age 39) |
| Chief Technology Officer | Giovanni Mambrini M.Sc. |
| Chief Scientific Officer | Guenter R. Janhofer |
Major Backers & Investors (QNCX)
Notable institutional backers of Quince Therapeutics, Inc. include Woodline Partners LP, Millennium Management, Shay Capital LLC, according to Nexqual as of June 10, 2026 at 02:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Woodline Partners LP | 3.19% |
| Millennium Management | 1.54% |
| Shay Capital LLC | 1.09% |
| Acadian Asset Management. LLC | 1.07% |
| Fidelity | 0.43% |
| IEQ Capital, LLC | 0.37% |
| Gen-wealth Partners Inc | 0.2% |
| Catalyst Funds Management Pty Ltd | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.56% |
| BlackRock | 0.37% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
From Quince Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-04-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
- The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
- Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AIXI | XIAO-I Corporation | USD 8.52 | ▼ 3.73% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.2 | ▲ 1.69% |
| VRAX | Virax Biolabs Group Limited | USD 0.19 | ▼ 11.64% |
| RENX | RenX Enterprises Corp. | USD 1.7 | ▼ 0.58% |
| MGRX | Mangoceuticals, Inc. | USD 0.34 | ▼ 4.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:25 UTC. This page is informational and not investment advice.